SubHero Banner

Jemperli (dostarlimab-gxly) – New indication

August 17, 2021 - GlaxoSmithKline announced the FDA approval of Jemperli (dostarlimab-gxly), for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

Download PDF